Long-term studies have shown that, on average, patients eventually lose best-corrected visual acuity. The HORIZON extension study documented adverse events and visual acuity results in patients treated with a VEGF inhibitor over 4 or more years. Rates of adverse events, including stroke and myocardial infarction, continued to be low with long-term treatment. Some visual acuity gains achieved with monthly treatment during the initial phases of the studies were lost as patients were followed and treated less frequently during the latter years of the HORIZON study.
Learn more about treatment of wet AMD with VEGF inhibitors.
Editor's Recommendations
Medscape © 2020 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: F. Ryan Prall. Fast Five Quiz: Exudative (Wet) Age-Related Macular Degeneration Management - Medscape - Nov 05, 2020.
Comments